Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Veklury® (remdesivir) formulations inhibit initial membrane‐coupled events of SARS‐CoV‐2 infection due to their sulfobutylether‐β‐cyclodextrin content

27 Feb 2023

Abstract excerpt

BACKGROUND AND PURPOSE: Despite its contradictory clinical performance, remdesivir (Veklury®) has a pivotal role in COVID-19 therapy. Possible contributions of the vehicle, sulfobutylether-β-cyclodextrin (SBECD) to Veklury® effects have been overlooked. The powder and solution formulations of Veklury® are treated equivalently despite their different vehicle content. Our objective was to study Veklury® effects on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Computational Drug Discovery Methods
Share to COVID-19 Clinical Research Studies
Share to Pharmacological Receptor Mechanisms and Effects

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36848880
DOI: 10.1111/bph.16063

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Veklury® (remdesivir) formulations inhibit initial membrane‐coupled events of SARS‐CoV‐2 infection due to their sulfobutylether‐β‐cyclodextrin contentPMID 36848880Read ↗

ACE2-Coated Virus-Like Particles Effectively Block SARS-CoV-2 InfectionSemantic proximity Read ↗

Edible formulations of chicken egg derived IgY antibodies neutralize SarsCoV2 Omicron RBD binding to human ACE2Semantic proximity Read ↗

Quantitative characterisation of extracellular vesicles designed to decoy or compete with SARS-CoV-2 reveals differential mode of action across variants of concern and highlights the diversity of OmicronSemantic proximity Read ↗

Clinical grade ACE2 effectively inhibits SARS-CoV-2 Omicron infectionsSemantic proximity Read ↗

ELV-N32 and RvD6 isomer decrease pro-inflammatory cytokines, senescence programming, ACE2 and SARS-CoV-2-spike protein RBD binding in injured corneaSemantic proximity Read ↗

Broad antiviral effects of <i>Echinacea purpurea</i> against SARS-CoV-2 variants of concern and potential mechanism of actionSemantic proximity Read ↗

Virofree, an Herbal Medicine-Based Formula, Interrupts the Viral Infection of Delta and Omicron Variants of SARS-CoV-2Semantic proximity Read ↗

Differential Activity of Repurposed Drugs as Receptor Binding Domain Antagonists for <i>Omicron</i> and Native Strains of SarsCov2Semantic proximity Read ↗

Genetically engineered MRI-trackable extracellular vesicles as SARS-CoV-2 mimetics for mapping ACE2 binding <i>in vivo</i>Semantic proximity Read ↗

Host-Directed Virus-Mimicking Particles Interacting with the ACE2 Receptor Competitively Block Coronavirus SARS-CoV-2 EntrySemantic proximity Read ↗

In a pathophysiologic state due to SARS-CoV-2, viscosity and cholesterol are two-edged swordsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.